The FDA has not approved a stem-cell therapy specifically for primary immunodeficiency as a licensed product, though investigational protocols are registered with the NIH. Gene therapy has recently received FDA approval for select severe immunodeficiencies (ADA-SCID, Wiskott-Aldrich syndrome), representing an alternative to stem-cell therapy. Hematopoietic stem-cell transplantation from matched donors remains the FDA gold-standard definitive treatment for select immunodeficiencies. Patients considering experimental stem-cell therapy should discuss approved alternatives with immunologists before committing.
Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity. Stem-cell research investigates whether fetal stem cells and placental mesenchymal stem cells can regenerate lymphoid tissue, promote T-cell and B-cell development within thymic or splenic niches, enhance phagocytic function, and restore immunological tolerance. With 91 registered trials and 13 currently recruiting, the biological rationale targets immune reconstitution through direct progenitor support and paracrine enhancement of developmental microenvironments. Early clinical data suggest potential for improving T-cell counts and function, enhancing antibody responses, reducing infection burden, and improving outcomes in severe combined immunodeficiency and other forms.
我是候选人吗？ → · Primary Immunodeficiency: full overview → · 原发性免疫缺陷成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估